Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Aglatimagene besadenovec by Candel Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Aglatimagene besadenovec is under clinical development by Candel Therapeutics and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to...
Aglatimagene besadenovec by Candel Therapeutics for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
Aglatimagene besadenovec is under clinical development by Candel Therapeutics and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According...
Aglatimagene besadenovec by Candel Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Aglatimagene besadenovec is under clinical development by Candel Therapeutics and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to...